I am testing compounds on the patient's primary cancer cells as well as a cell line. Generally, I see better activity in cell lines compared to primary cells. Surprisingly I am seeing the wonderful activity of few compounds in patient-derived primary cells but not in the cell lines. Could anybody please explain the possible reason for better activity in PDCs than cell lines?

More Bhawana Gupta's questions See All
Similar questions and discussions